NCT05504057 Antihistamines, Amantadine and Evolution of COVID-19
| NCT ID | NCT05504057 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Consorci Sanitari de Terrassa |
| Condition | COVID-19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 140,660 participants |
| Start Date | 2020-03-01 |
| Primary Completion | 2025-01-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 140,660 participants in total. It began in 2020-03-01 with a primary completion date of 2025-01-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
Eligibility Criteria
Inclusion Criteria: Patients having chronic treatment with antihistamines or amantadine - Exclusion Criteria: None \-
Contact & Investigator
Anna Puigdellívol, PhD
PRINCIPAL INVESTIGATOR
Terrassa Health Consortium
Frequently Asked Questions
Who can join the NCT05504057 clinical trial?
This trial is open to participants of all sexes, studying COVID-19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05504057 currently recruiting?
Yes, NCT05504057 is actively recruiting participants. Contact the research team at apuigdellivol@cst.cat for enrollment information.
Where is the NCT05504057 trial being conducted?
This trial is being conducted at Terrassa, Spain, Terrassa, Spain.
Who is sponsoring the NCT05504057 clinical trial?
NCT05504057 is sponsored by Consorci Sanitari de Terrassa. The principal investigator is Anna Puigdellívol, PhD at Terrassa Health Consortium. The trial plans to enroll 140,660 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.